KISS1: A Protein with Multiple Potential Applications (G3814)

Target Name: KISS1

NCBI ID: G3814

KISS1

KISS1: A Protein with Multiple Potential Applications

KISS1 (Hh13), also known as KIAA0902, is a protein that is expressed in various tissues throughout the body, including the brain, heart, and gastrointestinal tract. It is a member of the Kallikrein-related peptidases (KAPs) family, which includes several different proteins that play a role in the regulation of proteostasis, inflammation, and cellular signaling.

One of the unique features of KISS1 is its ability to interact with multiple protein targets, which has led to its potential as a drug target. KISS1 has been shown to interact with a wide range of proteins, including casein, alpha-actinin, and the protein kinase CKL3. This interactivity has implications for its potential as a therapeutic agent, as it may allow for the targeting of multiple proteins with a single drug.

In addition to its potential as a drug target, KISS1 has also been shown to be a valuable biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, KISS1 has been shown to be overexpressed in several types of cancer, including breast, lung, and colorectal cancer. This finding has implications for the development of new cancer therapies that target KISS1.

Another potential application of KISS1 is its role as a therapeutic agent for neurodegenerative diseases. KISS1 has been shown to interact with the protein alpha-synuclein, which is involved in the formation of beta-secretase aggregates that are a hallmark of neurodegenerative diseases. This suggests that KISS1 may be a useful target for therapies aimed at reducing the production of beta-secretase aggregates.

In addition to its potential as a drug and biomarker, KISS1 is also of interest to researchers who are studying the role of KAPs in cellular signaling. KISS1 has been shown to play a role in several signaling pathways, including the regulation of cell adhesion, migration, and invasion. This finding has implications for our understanding of the mechanisms that regulate these processes and may lead to new insights into the development of therapies aimed at modulating these processes.

Overall, KISS1 is a protein that has significant potential as a drug target and biomarker for a wide range of diseases. Its ability to interact with multiple protein targets and its potential as a therapeutic agent make it an attractive target for further research and development.

Protein Name: KiSS-1 Metastasis Suppressor

Functions: Metastasis suppressor protein in malignant melanomas and in some breast cancers. May regulate events downstream of cell-matrix adhesion, perhaps involving cytoskeletal reorganization. Generates a C-terminally amidated peptide, metastin which functions as the endogenous ligand of the G-protein coupled receptor GPR54. Activation of the receptor inhibits cell proliferation and cell migration, key characteristics of tumor metastasis. Kp-10 is a decapeptide derived from the primary translation product, isolated in conditioned medium of first trimester trophoblast. Kp-10, but not other kisspeptins, increased intracellular Ca(2+) levels in isolated first trimester trophoblasts. Kp-10 is a paracrine/endocrine regulator in fine-tuning trophoblast invasion generated by the trophoblast itself. The receptor is also essential for normal gonadotropin-released hormone physiology and for puberty. The hypothalamic KiSS1/GPR54 system is a pivotal factor in central regulation of the gonadotropic axis at puberty and in adulthood

The "KISS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KISS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets